Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Stomach Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Colorectal Neoplasms 3Neoplasms 2Breast Neoplasms 2Various Advanced Cancer 1Rectal Neoplasms 1Rectal Diseases 1Metastatic Adenocarcinoma of the Pancreas 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Trastuzumab 9Capecitabine 7trastuzumab deruxtecan 6Paclitaxel 6Fulvestrant 6pertuzumab 5eribulin 5Gemcitabine 4Cyclophosphamide 4sacituzumab govitecan 3Vinorelbine 3Doxorubicin 3Docetaxel 3Ado-Trastuzumab Emtansine 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2palbociclib 2olaparib 2larotrectinib 2exemestane 2abemaciclib 2Fluorouracil 2Epirubicin 2Carboplatin 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Breast Neoplasms × Fluorouracil × Clear all
NCT01358877 2025-11-28

APHINITY

Hoffmann-La Roche

Phase 3 Completed
4,804 enrolled 45 charts 1 FDA
Breast

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
596 enrolled 31 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡